The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -20,275 | -50,147 |
| Depreciation and amortization | 1,864 | 4,745 |
| Amortization (accretion) of premium (discount) on marketable securities | 111 | 300 |
| Stock-based compensation | 2,934 | 7,367 |
| Non-cash operating lease expense | 625 | 1,208 |
| Other | -63 | -230 |
| Prepaid expenses and other current assets | 774 | -1,488 |
| Other noncurrent assets | -65 | -508 |
| Accounts payable | -447 | -1,514 |
| Accrued and other current liabilities | 918 | -1,512 |
| Operating lease liabilities | -683 | -1,398 |
| Net cash used in operating activities | -15,599 | -38,725 |
| Purchases of property and equipment | 26 | 525 |
| Purchases of marketable securities | 0 | - |
| Proceeds from sales of marketable securities | 0 | 10,958 |
| Proceeds from maturities of marketable securities | 8,886 | 36,857 |
| Other | 0 | 0 |
| Net cash provided by (used in) investing activities | 8,860 | 47,290 |
| Proceeds from issuance of equity, net of issuance costs-Follow On Offering | 0 | 48,801 |
| Proceeds from exercise of stock options and employee stock purchase plan | 24 | 70 |
| Proceeds from exercise of warrants | 356 | - |
| Proceeds from exercise of prefunded warrants | 0 | - |
| Proceeds from issuance of equity, net of issuance costs-At The Market Offering | 0 | 912 |
| Net cash provided by financing activities | 380 | 49,783 |
| Net change in cash, cash equivalents and restricted cash | -6,359 | 58,348 |
| Cash and cash equivalents at beginning of period | 4,742 | - |
| Cash and cash equivalents at end of period | 56,731 | - |
Tenaya Therapeutics, Inc. (TNYA)
Tenaya Therapeutics, Inc. (TNYA)